Calixar and VirPath patent granted in the United States

CALIXAR announces the grant of its patent by the United States Patent and Trademark Office for the preparation of vaccine antigens using an innovative splitting approach for the formulation of novel vaccines (US 10144917 B2).

This patent issued from the fruitful collaboration with the academic laboratory VirPath is a great step forward in the generation of safer and more efficient vaccine candidates.

Share on facebook
Share on Facebook
Share on twitter
Share on Twitter
Share on linkedin
Share on LinkedIn

Contact us

Secure and boost your discovery programs.

Starting from native material or recombinant systems, we succeed with all types of membrane proteins: GPCRs, Ions Channels, Transporters, Receptors and Viral Proteins.

  • Conformational antibody development
  • Vaccine development
  • High-throughput ligand screening
  • Structure-based drug discovery
  • Immunoassays
  • Deorphanization projects
  • Identification of relevant targets
  • Expression of full-length membrane proteins
  • Functional isolation and stabilization of targets

© 2020 Calixar. All rights reserved.

Linkedin-in Youtube